PUBLISHER: The Business Research Company | PRODUCT CODE: 1825962
 
				PUBLISHER: The Business Research Company | PRODUCT CODE: 1825962
Convalescent plasma refers to plasma obtained from individuals who have recuperated from an infection and contains antibodies targeting the specific microorganism responsible for the infection. It is employed in the treatment of patients afflicted by the same pathogen.
The principal antibody categories utilized in convalescent plasma therapy are Immunoglobulin M (IgM), Immunoglobulin G (IgG), and Immunoglobulin A (IgA). Immunoglobulin A (IgA) is a crucial antibody for immune activities within mucous membranes. Convalescent plasma finds various applications, including preventive measures (prophylaxis) and treatment, and is applied across a range of sectors, including hospitals, clinics, laboratories, and research institutes.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The convalescent plasma therapy market research report is one of a series of new reports from The Business Research Company that provides convalescent plasma therapy market statistics, including convalescent plasma therapy industry global market size, regional shares, competitors with a convalescent plasma therapy market share, detailed convalescent plasma therapy market segments, market trends and opportunities, and any further data you may need to thrive in the convalescent plasma therapy industry. This convalescent plasma therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The convalescent plasma therapy market size has grown rapidly in recent years. It will grow from $0.05 billion in 2024 to $0.06 billion in 2025 at a compound annual growth rate (CAGR) of 11.1%. The growth in the historic period can be attributed to pandemics and infectious disease outbreaks, immunotherapy research, emergency use authorization (eua), patient availability, clinician and public awareness.
The convalescent plasma therapy market size is expected to see rapid growth in the next few years. It will grow to $0.09 billion in 2029 at a compound annual growth rate (CAGR) of 13.6%. The growth in the forecast period can be attributed to evolving pathogens, immunotherapies development, regulatory frameworks, global preparedness, public health initiatives. Major trends in the forecast period include standardized collection and processing, targeted plasma components, personalized treatment, telemedicine and remote monitoring, research into long-term effects.
The forecast of 13.6% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. infectious disease treatment by driving up the cost of plasma collection equipment and pathogen inactivation systems sourced from Brazil and Spain, exacerbating emergency preparedness costs during outbreaks. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
Higher efficacy and safety demonstrated during trials for convalescent plasma therapy (CPT) in COVID-19 patients are expected to drive market growth in the forecast period. Convalescent plasma therapy has been a subject of interest during various infectious disease outbreaks, such as SARS-1, Middle East Respiratory Syndrome (MERS), and 2009 H1N1. The results from studies, like the one conducted by Houston Methodist Hospital in June 2022, support its potential. The study indicated that convalescent plasma therapy was both safe (with no reported adverse events) and efficient, showing a 76% recovery rate for COVID-19 patients. In addition, a study published in the Journal of Medical Virology in May 2020 found that convalescent plasma therapy could potentially reduce mortality rates in critically ill patients, alleviate clinical symptoms, and lead to an increase in neutralizing antibody titers and the disappearance of SARS-CoV-2 RNA. As these studies confirm the safety and efficacy of CPT in treating COVID-19, the global convalescent plasma therapy market is poised for growth, driven by ongoing demand for treatments with proven benefits.
The increase in the number of hospitals is expected to propel the growth of the convalescent plasma therapy market. Hospitals are dedicated medical facilities providing a wide range of healthcare services, including diagnosis, treatment, and patient care. The rise in the number of hospitals often indicates improved healthcare infrastructure, offering better facilities for collecting, processing, and administering convalescent plasma. For instance, a report by Public Health Scotland in September 2022 indicated an increase in staffed beds for acute specialties, reaching an average of 13,323 in 2021/22, a 3.6% increase from the previous year (2020/21). Increased occupancy rates from 74.8% in 2020-21 to 84.2% in 2021/22 signify the growth in healthcare facilities. Therefore, the surge in hospital numbers is a key driver of the convalescent plasma therapy market.
The development of antibody-based immunotherapy for COVID-19 presents opportunities for the convalescent plasma therapy market. This therapy, which utilizes antibodies to enhance a patient's immunity, has garnered attention from companies investing in antibody-based COVID-19 treatments. For example, Regeneron Pharmaceuticals Inc. collaborated with the Biomedical Advanced Research and Development Authority (BARDA) to develop next-generation COVID-19 monoclonal antibody therapy. This focus on antibody-based COVID-19 therapy is likely to boost the convalescent plasma therapy market.
Major companies in the convalescent plasma therapy market are focusing on the development of innovative solutions, such as hyperimmune globulin therapies, to improve treatment efficacy and overcome the limitations of standard plasma therapies. Hyperimmune globulin therapies involve the use of plasma that is enriched with specific antibodies, typically collected from individuals who have recovered from a particular infection, offering potent and targeted immune support for patients. For example, in October 2023, Kamada Ltd., an Israel-based biopharmaceutical company, announced significant progress with its product CYTOGAM (Cytomegalovirus Immune Globulin Intravenous [Human]). After receiving FDA approval for its manufacturing facility in Israel, CYTOGAM became commercially available in the U.S. New clinical data presented at IDWeek 2023 revealed a five-year survival benefit for high-risk cytomegalovirus (CMV) mismatch lung transplant patients who received CYTOGAM. Additionally, Kamada formed its first Scientific Advisory Board to further enhance its U.S. clinical programs, positioning the company to make strides in the development of hyperimmune globulin therapies as a treatment for various infectious diseases. This move highlights the potential of hyperimmune globulin treatments to enhance convalescent plasma therapy and offer targeted, effective care for patients.
Major companies operating in the convalescent plasma therapy market include Bio Farma, Hilton Pharma Ltd., Biotest AG, BPL Ltd., LFB SA, Octapharma AG, CSL Behring LLC, Takeda Pharmaceutical Company Ltd., Orthosera Kft., ADMA Biologics Inc., GC Biopharma Corp, Grifols S.A, Sanquin Plasma Products B.V., America's Blood Centers, Blood Centers of America Inc., Anthem Inc., Laboratory Corporation of America Holdings, Cerus Corporation, Emergent BioSolutions Inc., Kedrion Biopharma Inc., New York Blood Center, Blood Systems Inc., OneBlood Inc., Gulf Coast Regional Blood Center, Bloodworks Northwest, Blood Assurance Inc., New York Blood Center Inc., Honolulu Blood-Plasma Bank, Community Blood Center, LifeStream Blood Bank
North America was the largest region in the convalescent plasma therapy market in 2024. Western Europe was the second largest region in the convalescent plasma therapy market. The regions covered in the convalescent plasma therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the convalescent plasma therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada
The convalescent plasma therapy market includes revenue earned by IgD and IgE. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Convalescent Plasma Therapy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on convalescent plasma therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for convalescent plasma therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The convalescent plasma therapy market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
 
                 
                 
                